SEER vs. AKYA, BNGO, RPID, OMIC, NAUT, PACB, COYA, NVCT, PDSB, and ADAG
Should you be buying Seer stock or one of its competitors? The main competitors of Seer include Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Rapid Micro Biosystems (RPID), Singular Genomics Systems (OMIC), Nautilus Biotechnology (NAUT), Pacific Biosciences of California (PACB), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), PDS Biotechnology (PDSB), and Adagene (ADAG). These companies are all part of the "medical" sector.
Seer (NASDAQ:SEER) and Akoya Biosciences (NASDAQ:AKYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
Akoya Biosciences has a net margin of -65.53% compared to Seer's net margin of -517.84%. Seer's return on equity of -20.87% beat Akoya Biosciences' return on equity.
Akoya Biosciences received 23 more outperform votes than Seer when rated by MarketBeat users. Likewise, 59.09% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Seer has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
In the previous week, Seer had 8 more articles in the media than Akoya Biosciences. MarketBeat recorded 10 mentions for Seer and 2 mentions for Akoya Biosciences. Akoya Biosciences' average media sentiment score of 0.78 beat Seer's score of 0.00 indicating that Akoya Biosciences is being referred to more favorably in the news media.
75.2% of Seer shares are held by institutional investors. Comparatively, 79.4% of Akoya Biosciences shares are held by institutional investors. 15.0% of Seer shares are held by insiders. Comparatively, 8.5% of Akoya Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Seer presently has a consensus price target of $7.00, indicating a potential upside of 300.00%. Akoya Biosciences has a consensus price target of $9.07, indicating a potential upside of 137.47%. Given Seer's higher probable upside, equities research analysts plainly believe Seer is more favorable than Akoya Biosciences.
Summary
Seer and Akoya Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Seer News Delivered to You Automatically
Sign up to receive the latest news and ratings for SEER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
